Prosigna has been added to the ESMO Clinical Practice Guidelines Annals of Oncology 26 (Supplement 5): v8–v30, 2015.
Prosigna receives Favorable Final Local Coverage Determination by Palmetto GBA for Its Prosigna Breast Cancer Assay
Publication of Clinical Study Demonstrating the Ability of Its Prosigna Breast Cancer Assay to Predict Response to Chemotherapy
NCCN Clinical Practice Guidelines for Breast Cancer Acknowledge Prosigna/PAM50 as Clinically Validated for Prediction of Prognosis
Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer.
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. (Ann Oncol)
St. Gallen International Breast Cancer Guidelines Recognize Power of Prosigna/PAM50 to Inform Treatment Decisions and Spare Low Risk Breast Cancer Patients Unnecessary Chemotherapy
Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From ABCSG-8 (JCO)
NanoString launches Prosigna Patient Support to help patients gain access to Prosigna.
Download the enrollment form today